Respiratory Medicine
Volume 104, Issue 10 , Pages 1425-1435 , October 2010

Montelukast added to fluticasone propionate does not alter inflammation or outcomes

  • Ratko Djukanović

      Affiliations

    • University of Southampton, Southampton, UK
    • Corresponding Author InformationCorresponding author. Southampton General Hospital, Tremona Road, Southampton SO16 6YD, United Kingdom. Tel.: +44 2380 794195; fax: +44 2380 777996.
    • ,
  • Susan J. Wilson

      Affiliations

    • University of Southampton, Southampton, UK
    • ,
  • Wendy C. Moore

      Affiliations

    • Wake Forest University School of Medicine, Division of Pulmonary and Critical Care Medicine, Winston-Salem, NC, USA
    • ,
  • Steven M. Koenig

      Affiliations

    • Charlottesville, VA, USA
    • ,
  • Michel Laviolette

      Affiliations

    • Laval Hospital and University, Quebec, Canada
    • ,
  • Eugene R. Bleecker

      Affiliations

    • Wake Forest University School of Medicine, Division of Pulmonary and Critical Care Medicine, Winston-Salem, NC, USA
    • ,
  • W. Bruce Davis

      Affiliations

    • Medical College of Georgia, Augusta, GA, USA
    • ,
  • Dennis E. Doherty

      Affiliations

    • University of Kentucky, Lexington, KY, USA
    • ,
  • Ronald Olivenstein

      Affiliations

    • Meakins Christie Laboratories, McGill University; Montreal, Canada
    • ,
  • Elliott Israel

      Affiliations

    • Brigham and Women’s Hospital, Harvard Medical School; Boston, MA, USA
    • ,
  • Mani S. Kavuru

      Affiliations

    • East Carolina University, Brody School of Medicine, Division of Pulmonary and Critical Care Medicine; Greenville, NC, USA
    • ,
  • Eric Kleerup

      Affiliations

    • Pulmonary Medicine Associates Sleep Center, Reno, NV, USA
    • ,
  • Donna S. Reilly

      Affiliations

    • GlaxoSmithKline, Respiratory Medicine Development Center, Research Triangle Park, NC, USA
    • ,
  • Steven W. Yancey

      Affiliations

    • GlaxoSmithKline, Respiratory Medicine Development Center, Research Triangle Park, NC, USA
    • ,
  • Lisa D. Edwards

      Affiliations

    • GlaxoSmithKline, Respiratory Medicine Development Center, Research Triangle Park, NC, USA
    • ,
  • John L. Stauffer

      Affiliations

    • CV Therapeutics, Palo Alto, CA, USA
    • ,
  • Paul M. Dorinsky

      Affiliations

    • Teva USA, Horsham, PA, USA
    • ,
  • Nizar N. Jarjour

      Affiliations

    • University of Wisconsin School of Medicine and Public Health, Section of Allergy, Pulmonary and Critical Care, Madison, WI, USA

Received 20 August 2009 ,Accepted 5 April 2010.

References 

  1. British Thoracic Society . Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2003;58(Suppl. 1):1l–94
  2. GINA Report . Global strategy for asthma management and prevention. From the global strategy for asthma management and prevention. Global Initiative for Asthma (GINA); 2006;Available from: http://www.ginasthma.org
  3. National Asthma Education and Prevention Program . Executive summary of the NAEEP expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; June 2007;NIH Publication No. 07-4051
  4. Sousa A, Poston R, Lane S, Nakhosteen J, Lee T. Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids. Am Rev Respir Dis. 1993;147:1447–1461
  5. Sue-Chu M, Wallin A, Wilson S, Ward J, Sandstrom T, Djukanovic R, et al. Bronchial biopsy study in asthmatics treated with low and high-dose fluticasone propionate (FP) compared to low-dose FP combined with salmeterol. Eur Respir J. 1999;S30:124
  6. Barnes P. How corticosteroids control inflammation: Quintiles Prize lecture 2005. Br J Pharmacol. 2006;148:245–254
  7. Barnes P. Current issues for establishing inhaled corticosteroids as the anti-inflammatory agents of choice in asthma. J Allergy Clin Immunol. 1998;101:S427–S433
  8. Calhoun W, Lavins B, Minkwitz M, Evans R, Gleich G, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation. Am J Respir Crit Care Med. 1998;157:1381–1389
  9. Hasday J, Meltzer S, Moore W, Wisniewski P, Hebel J, Lanni C, et al. Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. Am J Respir Crit Care Med. 2000;61:1229–1236
  10. Laviolette M, Malmstrom K, Lu S, Chervinski P, Pujet J, Peszek I, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 1999;160:1862–1868
  11. Vaquerizo M, Casan P, Castillo J, Perpina M, Sanchis J, Sobradillo V, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003;58:204–210
  12. Drazen J, Israel E, O’Byrne P. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999;340:197–206
  13. Green R, Brightling C, McKenna S, Hargadon B, Neale N, Parker D, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J. 2006;27:1144–1151
  14. Green R, Brightling C, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial. Lancet. 2002;360:1715–1721
  15. Pizzichini E, Pizzichini M, Leigh R, Djukanovic R, Strek P. Safety of sputum induction. Eur Respir J. 2002;20(Suppl. 37):9s–18s
  16. Jarjour N, Wilson S, Koenig S, Laviolette M, Moore W, Davis W, et al. Control of airway inflammation maintained at a lower steroid dose with 100/50μg of fluticasone propionate/salmeterol. J Allergy Clin Immunol. 2006;118:44–52
  17. Britten KM, Howarth PH, Roche WR. Immunohistochemistry on resin sections: a comparison of resin embedding techniques for small mucosal biopsies. Biotech Histochem. 1993;68:271–280
  18. Sullivan P, Stephens D, Ansari T, Costello J, Jeffery P. Variation in measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. Eur Resp J. 1998;12:811–815
  19. Moore W, Hasday J, Meltzer S, Wisnewski P, White B, Bleecker E. Subjects with mild and moderate asthma respond to segmental allergen challenge with similar, reproducible, allergen specific inflammation. J Allergy Clin Immunol. 2001;108:908–914
  20. Kraft M, Martin R, Lazarus S, Fahy J, Boushey H, Lemanske R, et al. Airway tissue mast cells in persistent asthma: predicator of treatment failure when patients discontinue inhaled corticosteroids. Chest. 2003;124:42–50
  21. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Oliveri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest. 1997;111:852–857
  22. Efron B, Tibshirani R. An introduction to the bootstrap. London: Chapman and Hall; 1993;
  23. Ward C. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 2002;57:309–316
  24. Van den Toorn L. Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. Respir Med. 2005;99:779–787
  25. Ward C. Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis. Clin Exp Allergy. 2005;35:1565–1571
  26. Capraz F. The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics. Lung. 2007;185:89–96
  27. Pavord I. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. J Allergy Clin Immunol. 2009;123:1083–1089
  28. Laitinen A. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med. 1997;156:951–958
  29. Hoshino M. Inhaled corticosteroid reduced lamina reticularis of the basement by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma. Clin Exp Allergy. 1998;28:568–577
  30. Hoshino M. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immuol. 1999;104:356–363
  31. Orsida B. Effect of a long-acting β2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med. 2001;164:117–121
  32. Boulet L-P. Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Am J Respir Crit Care Med. 2000;162:1308–1313
  33. Olivieri D. Effect of short-term treatment with low dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med. 1997;155:1864–1871
  34. O’Sullivan S, Akveld M, Burke C, Poulter L. Effects of addition of montelukast to inhaled fluticasone propionate on airway inflammation. Am J Repir Crit Care Med. 2003;167:745–750
  35. Leigh R, Vethanayagam D, Yoshida M, Watson R, Rerecich T, Inman M, et al. Effects of montelukast and budesonide on airway response and airway inflammation in asthma. Am J Respir Crit Care Med. 2002;166:1212–1217
  36. Robinson D, Campbell D, Barnes PJ. Addition of leukotrienes antagonists to therapy in chronic persistent asthma: a randomized double-blind placebo-controlled trial. Lancet. 2001;357:2007–2011
  37. Vignola A. Effects of inhaled corticosteroids, leukotriene receptor antagonist, or both, plus long-acting beta2-agonist on asthma pathophysiology: a review of the current evidence. Drugs. 2003;63(Suppl. 2):35–51
  38. Djukanovic R, Wilson J, Britten K, Wilson S, Wall A, Roche W, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992;145:669–674
  39. Sont J, Willems L, Bel E, van Kreiken J, Vandenbrouke J, Sterke P, et al. Clinical Control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med. 1999;159:1043–1051
  40. Ronald N, Bhalla R, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213–219
  41. Yildrum Z, Ozlu T, Bulbul Y, Bayram H. Addition of montelukast versus double dose of inhaled budesonide in moderate persistent asthma. Respirology. 2004;9:243–248
  42. Perng DW, Huang HY, Lee YC, Perna RP. Leukotriene modifier vs inhaled corticosteroid in mild to moderate asthma: clinical and anti-inflammatory effects. Chest. 2004;125:1693–1699
  43. Barnes N, Laviolette M, Allen D, Flood-Page P, et al. Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control. Respir Med. 2007;101:1652–1658
  44. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. Br Med J. 2002;324:1545–1548
  45. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. 2005;1:CD003137
  46. Green RH, Brightling CE, McKenna S, Hargadon B, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J. 2006;27:1144–1151
  47. Schleimer R. Glucocorticoids supress inflammation but spare innate immune responses in airway epithelium. Proc Am Thorc Soc. 2004;1:222–230
  48. Funk C, et al. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871–1875

PII: S0954-6111(10)00157-5

doi: 10.1016/j.rmed.2010.04.004

Respiratory Medicine
Volume 104, Issue 10 , Pages 1425-1435 , October 2010

Article Tools

* Image Usage & Resolution